International Myeloma Society 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026

The 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop, hosted by the International Myeloma Society (IMS), is a specialized scientific convening held from March 27-28, 2026, at the Boston Marriott Long Wharf in Boston, MA. This workshop brings together leading clinical and experimental scientists to discuss the latest advancements, real-world data, and future directions of immune therapies for multiple myeloma. The program offers an in-depth exploration of CAR T cells, bispecific antibodies, resistance mechanisms, toxicity management, and novel in vivo approaches. It provides both in-person and on-demand access to scientific sessions, fostering global education and collaboration in the field.
Learning Objectives
Upon completion of this workshop, participants will be able to:

Evaluate the latest clinical updates and real-world data for various CAR T cell therapies (Ide-cel, Cilta-cel, Anito-cel, GC012F) and bispecific antibodies (Teclistamab, Talquetamab, Elranatamab, Linvoseltamab).

Analyze novel therapeutic approaches, including trispecific antibodies, combination therapies, and dual-targeted CAR T cells.

Identify and manage toxicities associated with T cell engaging therapies, such as CAR-T-associated delayed neurotoxicity and immune effector cell enterocolitis.

Understand the genomic drivers and microenvironmental factors contributing to response and resistance in BCMA and GPRC5D-targeted therapies.

Apply practical strategies for optimizing the administration and sequencing of immune therapies in clinical settings.

Target Audience
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
Best for hematologists, medical oncologists, immunologists, clinical researchers, and scientists.
Topics

SESSION 1: CLINICAL UPDATES ON CART CELLS

Ide-cel and Cilta-cel: Latest Updates and Ongoing Trials

Latest Real World Data for CAR T Cells

Update on Anito-cel and GC012F

GPRC5D CAR T Cells: Latest Updates and Ongoing Trials

Dual-targeted CAR T Cell Approaches

Update on Allogeneic CAR T Cell Approaches

SESSION 2: CLINICAL UPDATES ON BISPECIFIC ANTIBODIES

Teclistamab and Talquetamab for Relapsed MM: Latest Updates and Ongoing Trials

Elranatamab and Linvoseltamab for Relapsed MM: Latest Updates and Ongoing Trials

Real World Data for Bispecific Antibodies

Bispecific Abs for First-line and Maintenance Therapy

Etentamig and Cevostamab: Latest Updates and Ongoing Trials

SESSION 3: NOVEL APPROACHES IN THE CLINIC

Trispecific Antibodies for Myeloma

Combining Bispecific Abs with CAR T Cells

Fixed Duration Bispecific Antibody Therapy

Augmenting T Cell Therapies with Proteasome Inhibitors

TriPRIL CAR T Cells

Bispecific with Anti-CD38 Antibody

SESSION 4: TOXICITIES OF T CELL ENGAGING THERAPIES

Pre-treatment Parameters Predicting CAR T Cell Toxicities

Elevated ALC and CAR T Cell Toxicities

Managing CAR-T-associated Delayed Neurotoxicity

CAR T-related Lymphomas: Clinical and Mechanistic Insights

SESSION 5: PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPIES

Sequencing BCMA-directed Therapies: How to Choose?

Optimizing Outpatient Bispecific Ab and CAR T Cell Administration

Managing Extramedullary Disease with T cell-redirecting Therapies

T Cell Therapies for CNS Myeloma

Impact of CHIP on Outcomes after CAR T Cell Therapy

SESSION 6: UNDERSTANDING RESPONSE AND RESISTANCE TO T CELL THERAPIES

Genomic Drivers of Resistance to BCMA-targeted Therapies

Mechanisms of Antigen Escape following GPRC5D-targeted Therapies

Immune Correlates of Response to BCMA CAR T Cells

Microenvironmental Factors Impacting Response/resistance

Immune Correlates of Resistance to Bispecific Antibodies

SESSION 7: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 1

Evaluating Immune Fitness Across the Stages of MM Progression

Targeting S100A8/9 to Enhance T Cell Therapies

Overcoming T Cell Exhaustion

Modulating the Microbiome to Enhance CAR T Cell Therapy

SESSION 8: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 2

Novel T Cell Therapy Targets for Myeloma

CAR T Cells Against CD70

Targeting Intra-cellular Targets

EZH1/2 inhibition to augment cellular therapy

Engingeering of First in Class CAR Bugs for Cancer Immunotherapy

SESSION 9: CHALLENGING CASES IN IMMUNE EFFECTOR CELL THERAPY

CAR T Cell Therapy in a Patient with Plasma Cell Leukemia

Immune Effector Cell Enterocolitis: A Novel Clonal Lymphoproliferative Disorder?

Fatal HLH Following GPRC5D×CD3 Therapy: Lessons from Genetic and Infectious Co-factors

SESSION 10: IN VIVO APPROACHES

Science of In Vivo CAR T Cell Therpay

Bedside CAR T Cell Production

In Vivo Bispecific Therapy

Clinical Results of In Vivo CAR T Cell Therapy

Clinical Results of In Vivo CAR T Cell Therapy Part II